Journal article
Phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer
M Ciprotti, NC Tebbutt, FT Lee, ST Lee, HK Gan, DC McKee, GJ O'Keefe, SJ Gong, G Chong, W Hopkins, B Chappell, FE Scott, MW Brechbiel, AN Tse, M Jansen, M Matsumura, M Kotsuma, R Watanabe, R Venhaus, RA Beckman Show all
Journal of Clinical Oncology | Published : 2015
Abstract
Purpose: CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 (111In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time point..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
Supported by Daiichi Sankyo Co., Ltd.